FDA Guidances Part of Charm Offensive to Woo Compounders

Drug Industry Daily
The flurry of FDA guidance issued this week explaining to compounders how to work with the FDA is part of the agency’s full-on effort to make registration as appealing as possible to compounders who may worry that regulatory oversight will hamper business.

To View This Article:


Subscribe To Drug Industry Daily